{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T13:36:22Z","timestamp":1649079382626},"reference-count":10,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,26]]},"DOI":"10.1182\/blood-2016-12-753145","type":"journal-article","created":{"date-parts":[[2017,1,26]],"date-time":"2017-01-26T12:30:11Z","timestamp":1485433811000},"page":"402-403","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent mutations and targeted therapy in FL"],"prefix":"10.1182","volume":"129","author":[{"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111903224932400_B1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111903224932400_B2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111903224932400_B3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1182\/blood-2015-12-682591","article-title":"Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations","volume":"128","author":"Louissaint","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111903224932400_B4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/cas.12392","article-title":"Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis","volume":"105","author":"Takata","year":"2014","journal-title":"Cancer Sci"},{"issue":"9","key":"2019111903224932400_B5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903224932400_B6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10637-015-0206-x","article-title":"Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia","volume":"33","author":"Morschhauser","year":"2015","journal-title":"Invest New Drugs"},{"issue":"23","key":"2019111903224932400_B7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.473.473","article-title":"Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of Zeste-homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin lymphoma (NHL) patients [abstract]","volume":"126","author":"Ribrag","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2019111903224932400_B8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111903224932400_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial [abstract]","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111903224932400_B10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/4\/402\/1401792\/blood753145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/4\/402\/1401792\/blood753145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:23:08Z","timestamp":1574133788000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/4\/402\/36187\/Recurrent-mutations-and-targeted-therapy-in-FL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,26]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-12-753145","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,26]]}}}